Using muscle assessment to predict health outcomes in liver disease patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the Muscle Assessment Score (MAsS) using MRI as an objective measure of frailty and muscle composition in patients with liver disease. It will involve a prospective analysis of patients already scheduled for MRI at the University of Chicago Medical Center, focusing on four specific groups: those hospitalized with acute hepatic decompensation, patients with hepatobiliary neoplasia, individuals undergoing TIPS placement, and those with chronic liver disease. The MAsS assessment will add an additional 8-10 minutes to the MRI procedure, allowing researchers to gather valuable data on the correlation between muscle composition and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated

Exclusion Criteria:

* \<18 yrs. of age

Where it's running

• The University of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Omar Jamil, MD
• Email: Omar.Jamil@uchospitals.edu
• Phone: 847-373-2360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Safety and how the drug behaves in adults with moderate to severe liver impairment

  This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.

  Recruiting at 4 sites Phase 1 Incyte Corporation · Chandler, Arizona and 3 other locations · NCT07559474

• Single-probe FibroScan for measuring liver stiffness

  This project will try a single-probe FibroScan to measure liver stiffness in adults with chronic liver disease and compare its results to the standard M and XL probes.

  Recruiting Echosens · Besançon and 3 other locations · NCT07400289

• Using polyene phosphatidylcholine to protect the liver after hepatectomy

  This test checks whether giving polyene phosphatidylcholine before surgery plus magnesium isoglycyrrhizinate after surgery better prevents liver injury in people having laparoscopic liver resection for hepatocellular carcinoma.

  Recruiting Phase 4 Anhui Provincial Hospital · Hefei, Anhui · NCT07150624

• CRISPR-edited donor liver transplant to reduce rejection

  This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053488

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.